biolimus

Access Denied
Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary InterventionA Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial)
Michael Maeng, Johnny Kahlert, et al.

JACC: Cardiovascular Interventions
Access Denied
Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial
Bent Raungaard, Lisette Okkels Jensen, et al.

JACC: Cardiovascular Interventions
Access Denied
Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial
Ricardo A. Costa, BioFreedom FIM Clinical Trial Investigators, et al.

JACC: Cardiovascular Interventions

Advertisement